For patients with severe mitral regurgitation requiring surgery, the choice between mitral valve repair and mitral valve replacement is one of the most consequential decisions in cardiac surgery. When feasible, repair is strongly preferred — it preserves native valve tissue, maintains left ventricular geometry, avoids prosthesis-related complications, and is associated with better long-term survival. The 2020 ACC/AHA Guidelines give mitral repair a Class I recommendation over replacement for degenerative mitral regurgitation. However, not all mitral valves can be repaired. The feasibility and durability of repair depend on the etiology (degenerative vs functional vs rheumatic), the specific leaflet pathology, annular calcification, and critically, the experience of the surgeon. Reference centers report repair rates exceeding 95% for degenerative disease, while community hospitals may achieve only 50-60%. Understanding when repair is possible, when replacement is necessary, and what constitutes an adequate repair requires expert surgical judgment — making this one of the most important areas for a second opinion in cardiac surgery.
Mitral valve repair reconstructs the patient's own valve using a combination of techniques: annuloplasty ring placement, leaflet resection, chordal transfer or replacement with Gore-Tex neochordae, edge-to-edge repair (Alfieri stitch), and commissuroplasty. The goal is to restore normal leaflet coaptation and eliminate regurgitation while preserving native tissue and subvalvular apparatus.
Mitral valve replacement removes the diseased valve leaflets (ideally preserving the subvalvular apparatus) and implants a mechanical or bioprosthetic prosthesis. It is the definitive option when repair is not feasible or durable. The choice between mechanical and bioprosthetic replacement follows the same considerations as aortic valve prosthesis selection — durability vs anticoagulation burden.
The 2020 ACC/AHA Guidelines give mitral valve repair a Class I recommendation over replacement for patients with chronic severe primary (degenerative) MR when a durable repair can be achieved. Referral to an experienced surgical center with demonstrated high repair rates (>95%) and low mortality (<1%) is recommended when repair is expected (Class I). For secondary (functional/ischemic) MR, the guidelines note repair has higher recurrence rates and replacement may be preferred.
The repair vs replacement decision is perhaps the most surgeon-dependent decision in cardiac surgery. Surgeon experience and institutional repair rates are the strongest predictors of repair feasibility and durability. A cardiologist provides detailed echocardiographic assessment of valve anatomy (Barlow's, fibroelastic deficiency, commissural disease), while the surgeon evaluates repairability. WhiteGloveMD provides a second opinion on whether repair is feasible, and whether the patient should seek a referral to a high-volume mitral repair center.
Mitral valve repair is strongly preferred over replacement for degenerative mitral regurgitation — it offers better survival, no anticoagulation, and preserved ventricular function. However, repair feasibility depends on valve pathology and surgeon expertise. Patients should ask about their surgeon's personal repair rate and consider referral to a reference center. For functional/ischemic MR, the repair vs replacement calculus is different, with replacement sometimes preferred due to high repair recurrence rates.
Degenerative mitral valve disease (prolapse, flail leaflet) is highly repairable, with reference centers achieving >95% repair rates. Rheumatic, heavily calcified, or complex bileaflet disease is more challenging. A detailed echocardiogram and evaluation by an experienced mitral surgeon are essential.
Repair rate is the percentage of mitral surgeries where the surgeon performs a repair rather than replacement. Centers with >95% repair rates have better outcomes. National repair rates remain around 65%, meaning many patients receive replacements that could have been repairs at an experienced center.
Early repair failure (operative) may require conversion to replacement during the same surgery. Late repair failure (years later) can be addressed with redo repair, replacement, or in some cases MitraClip. Overall freedom from reoperation after degenerative repair is 90-96% at 10-20 years at experienced centers.
For degenerative MR, repair is clearly preferred when durable repair is achievable. For ischemic/functional MR, the CTSN trial showed higher MR recurrence after repair (58.8% vs 3.8%), so replacement may be preferred. The etiology of MR is the key distinction.
Our Heart Team evaluates your specific anatomy, risk factors, and goals to recommend the best approach. 48-hour turnaround.